Abstract
Cardiotoxicity encompasses a spectrum of adverse cardiological effects experienced by cancer patients during and after receiving antineoplastic treatments. The intersection of cancer care with the management of the multiple comorbid non-communicable diseases carried by patients or related to cancer treatments motivates the need for an integrated and multidisciplinary approach to therapeutic clinical decision-making. This present review aimed to provide a perspective and an update of the current pharmacotherapy approaches for the prevention and management of cardiotoxicity from antiblastic chemotherapy; as such, it addresses myocardial, vascular, and arrhythmic disorders associated to chemotherapy, by navigating the current knowledge and clinical indications in support of the medical interventions. Clinical scenarios of pharmacological interventions take place with patients receiving anthracycline and, by extrapolation, other agents with cardiotoxic potentials and non-chemotherapy agents, including various small molecules and immunotherapy agents. Analysis of these scenarios aims to provide practical evidence-based guidance for the management of drug-induced cardiac dysfunctions. The possible role of new biomarkers for the early recognition of cardiotoxicity is mentioned across the clinical studies, with reference to the pharmacological biomarker-driven interventions delivered. To best inform survivorship care, the management and context of cardio-oncology services are discussed within the broader network of providers and settings of care.
Highlights
The improvement of early diagnosis and timely cancer treatments has resulted in an improvement of the cancer survival rate in the last decade, with a growing population of cancer survivors
The quality of data used to guide the clinical decisions regarding the appropriate clinical strategies of prevention and control of the cardiovascular sequelae in cancer survivors is still scarce and is widely based on experts’ consensus. This motivates the urgent need for research in cardio-oncology
This present review aims to discuss key points for the management of patients treated with chemotherapy agents and experiencing one or more cardiovascular treatment-related toxicities at some point during the
Summary
The improvement of early diagnosis and timely cancer treatments has resulted in an improvement of the cancer survival rate in the last decade, with a growing population of cancer survivors. Cancer survivors can carry a multitude of treatment-related comorbidities, including cardiovascular toxicities [1]. The quality of data used to guide the clinical decisions regarding the appropriate clinical strategies of prevention and control of the cardiovascular sequelae in cancer survivors is still scarce and is widely based on experts’ consensus. This motivates the urgent need for research in cardio-oncology. This present review aims to discuss key points for the management of patients treated with chemotherapy agents and experiencing one or more cardiovascular treatment-related toxicities at some point during the.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
